Medicinova (MNOV) Income from Continuing Operations (2010 - 2026)
Medicinova (MNOV) posted quarterly Income from Continuing Operations of 2793526.0 for Q4 2025, up 15.18% year-over-year from 2425279.61 in Q4 2024, and up 13.1% quarter-over-quarter from 3214575.0 in Q3 2025.
Medicinova (MNOV) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Income from Continuing Operations for 16 consecutive years, with 2793526.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 15.18% year-over-year to 2793526.0; the TTM figure through Dec 2025 stood at 12871982.0 (down 5.42% YoY), while the FY2025 annual figure was 9473651.0, up 21.38% from the prior year.
- Income from Continuing Operations climbed to 2793526.0 in Q4 2025 per MNOV's latest filing, from 3214575.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 226526.0 in Q1 2021 and bottomed at 85420679.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 7253897.8 across 5 years, with a median of 3214828.0 in 2023.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations jumped 99.68% — and 2023, when it plunged 2946.46%.
- Medicinova's Income from Continuing Operations stood at 2489643.0 in 2021, then retreated by 12.62% to 2803931.0 in 2022, then slumped by 2946.46% to 85420679.0 in 2023, then surged by 96.14% to 3293618.0 in 2024, then grew by 15.18% to 2793526.0 in 2025.
- Business Quant data shows MNOV's Income from Continuing Operations at 2793526.0 in Q4 2025, 3214575.0 in Q3 2025, and 3609146.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 | -2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.43 Mn |
| Dec 31, 2025 | -2.79 Mn |
| Sep 30, 2025 | -3.21 Mn |
| Jun 30, 2025 | -3.61 Mn |
| Mar 31, 2025 | -3.25 Mn |
| Dec 31, 2024 | -3.29 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -3.17 Mn |
| Mar 31, 2024 | -2.82 Mn |
| Dec 31, 2023 | -85.42 Mn |
| Sep 30, 2023 | -1.49 Mn |
| Jun 30, 2023 | -3.06 Mn |
| Mar 31, 2023 | -3.22 Mn |
| Dec 31, 2022 | -2.80 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.18 Mn |
| Mar 31, 2022 | -3.58 Mn |
| Dec 31, 2021 | -2.49 Mn |
| Sep 30, 2021 | -4.67 Mn |
| Jun 30, 2021 | -4.34 Mn |